BR0107869A - Electrogenated pharmaceutical compositions - Google Patents

Electrogenated pharmaceutical compositions

Info

Publication number
BR0107869A
BR0107869A BR0107869-0A BR0107869A BR0107869A BR 0107869 A BR0107869 A BR 0107869A BR 0107869 A BR0107869 A BR 0107869A BR 0107869 A BR0107869 A BR 0107869A
Authority
BR
Brazil
Prior art keywords
electrogenated
pharmaceutical compositions
electrogirated
therapy
directed
Prior art date
Application number
BR0107869-0A
Other languages
Portuguese (pt)
Inventor
Francis Ignatious
John M Baldoni
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of BR0107869A publication Critical patent/BR0107869A/en

Links

Classifications

    • D—TEXTILES; PAPER
    • D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
    • D01D—MECHANICAL METHODS OR APPARATUS IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS
    • D01D5/00—Formation of filaments, threads, or the like
    • D01D5/0007—Electro-spinning
    • D01D5/0015—Electro-spinning characterised by the initial state of the material
    • D01D5/003—Electro-spinning characterised by the initial state of the material the material being a polymer solution or dispersion
    • D01D5/0038—Electro-spinning characterised by the initial state of the material the material being a polymer solution or dispersion the fibre formed by solvent evaporation, i.e. dry electro-spinning
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • D—TEXTILES; PAPER
    • D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
    • D01D—MECHANICAL METHODS OR APPARATUS IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS
    • D01D5/00—Formation of filaments, threads, or the like
    • D01D5/0007—Electro-spinning
    • D01D5/0015—Electro-spinning characterised by the initial state of the material
    • D01D5/0023—Electro-spinning characterised by the initial state of the material the material being a polymer melt
    • D—TEXTILES; PAPER
    • D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
    • D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
    • D01F1/00—General methods for the manufacture of artificial filaments or the like
    • D01F1/02—Addition of substances to the spinning solution or to the melt
    • D01F1/10—Other agents for modifying properties

Abstract

"COMPOSIçõES FARMACêUTICAS ELETROGIRADAS". A presente invenção é direcionada para uma composição farmacêutica eletrogirada compreendendo um agente ativo aceitável farmaceuticamente e um carreador polimérico aceitável para uso em terapia."ELECTROGIRATED PHARMACEUTICAL COMPOSITIONS". The present invention is directed to an electrogenated pharmaceutical composition comprising a pharmaceutically acceptable active agent and an acceptable polymeric carrier for use in therapy.

BR0107869-0A 2000-01-28 2001-01-25 Electrogenated pharmaceutical compositions BR0107869A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17868200P 2000-01-28 2000-01-28
PCT/US2001/002399 WO2001054667A1 (en) 2000-01-28 2001-01-25 Electrospun pharmaceutical compositions

Publications (1)

Publication Number Publication Date
BR0107869A true BR0107869A (en) 2002-11-05

Family

ID=22653497

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0107869-0A BR0107869A (en) 2000-01-28 2001-01-25 Electrogenated pharmaceutical compositions

Country Status (18)

Country Link
EP (1) EP1251829A4 (en)
JP (1) JP2003521493A (en)
KR (1) KR100806412B1 (en)
CN (1) CN1223340C (en)
AR (1) AR028204A1 (en)
AU (1) AU772830B2 (en)
BR (1) BR0107869A (en)
CA (1) CA2396640A1 (en)
HU (1) HUP0301130A3 (en)
IL (1) IL150642A0 (en)
MX (1) MXPA02007298A (en)
MY (1) MY129356A (en)
NO (1) NO20023338L (en)
NZ (1) NZ519992A (en)
PL (1) PL356924A1 (en)
TW (1) TWI289061B (en)
WO (1) WO2001054667A1 (en)
ZA (1) ZA200205989B (en)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9910505D0 (en) 1999-05-06 1999-07-07 Electrosols Ltd A method and apparatus for manufacturing consumable tablets
WO2002032397A2 (en) * 2000-10-18 2002-04-25 Virginia Commonwealth University Intellectual Property Foundation Electroprocessing in drug delivery and cell encapsulation
JP2010163435A (en) * 2000-11-17 2010-07-29 Virginia Commonwealth Univ Intellectual Property Foundation Electroprocessed collagen
ATE402002T1 (en) * 2000-11-17 2008-08-15 Univ Virginia Commonwealth ELECTROPROCESSED COLLAGEN
ATE473082T1 (en) * 2001-03-20 2010-07-15 Nicast Ltd PORTABLE ELECTROSPINNER DEVICE
US6685956B2 (en) * 2001-05-16 2004-02-03 The Research Foundation At State University Of New York Biodegradable and/or bioabsorbable fibrous articles and methods for using the articles for medical applications
GB0123951D0 (en) * 2001-10-05 2001-11-28 Glaxo Group Ltd Therapies for treating respiratory diseases
BR0307344A (en) 2002-02-01 2004-12-14 Pfizer Prod Inc Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase forming materials
KR100549140B1 (en) 2002-03-26 2006-02-03 이 아이 듀폰 디 네모아 앤드 캄파니 A electro-blown spinning process of preparing for the nanofiber web
KR101027550B1 (en) 2002-04-04 2011-04-06 더 유니버시티 오브 아크론 Non-woven fiber assemblies
US8367570B2 (en) 2002-04-04 2013-02-05 The University Of Akron Mechanically strong absorbent non-woven fibrous mats
WO2003087443A1 (en) * 2002-04-11 2003-10-23 Secant Medical, Inc. Covering process using electrospinning of very small fibers
US20060083784A1 (en) * 2002-08-07 2006-04-20 Smithkline Beecham Corporation Amorphous pharmaceutical compositions
TW200410714A (en) * 2002-08-07 2004-07-01 Smithkline Beecham Corp Electrospun amorphous pharmaceutical compositions
US7842780B2 (en) 2003-01-07 2010-11-30 Trustees Of Tufts College Silk fibroin materials and use thereof
JP2007501218A (en) 2003-08-04 2007-01-25 ファイザー・プロダクツ・インク Pharmaceutical composition of adsorbate of amorphous drug and lipophilic microphase-forming substance
WO2005065657A2 (en) 2003-12-31 2005-07-21 Pfizer Products Inc. Solid compositions of low-solubility drugs and poloxamers
JP4526851B2 (en) * 2004-03-31 2010-08-18 明彦 谷岡 Polysaccharide nanoscale fibers and compacts
WO2006006746A1 (en) * 2004-07-09 2006-01-19 Hak-Yong Kim Polymer particles, and a method for manufacturing the same
CN100577720C (en) * 2005-03-21 2010-01-06 中国科学院化学研究所 Biodegradable and absorb polymer nano fibrous membrane materials and method for making and purposes
JP2006299459A (en) * 2005-04-20 2006-11-02 National Institute For Materials Science Method for producing biodegradable polymer nonwoven fabric tube
CN1300393C (en) * 2005-07-01 2007-02-14 中国科学院长春应用化学研究所 Preparation method of ultrafine fiber medical agent type emulsion electro spinning fiber
US20090107495A1 (en) * 2005-07-21 2009-04-30 National Institute For Materials Science Device for inhalation of medicine
JP4787585B2 (en) * 2005-09-29 2011-10-05 帝人株式会社 Manufacturing method of fiber structure by electrostatic spinning method
CN100556399C (en) * 2005-12-23 2009-11-04 中国科学院广州化学研究所 A kind of intestine target medicinal controlled release fiber and preparation method thereof
US8367112B2 (en) 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
KR100824719B1 (en) * 2006-09-04 2008-04-24 주식회사 아모메디 Bio-degradable food-packing materials consisting of starch-contained nonwoven-nanofabrics and preparation methods therefor
WO2009120365A2 (en) 2008-03-27 2009-10-01 Agigma, Inc. Methods and compositions for the delivery of agents
ES2640162T3 (en) 2008-04-16 2017-11-02 The Procter & Gamble Company Composition for non-foaming personal hygiene in the form of an article
WO2010015709A2 (en) 2008-08-08 2010-02-11 Basf Se Fibrous surface structure containing active ingredients with controlled release of active ingredients, use thereof and method for the production thereof
EP2328567A2 (en) 2008-08-08 2011-06-08 Basf Se Continuous fiber layer comprising an active substance on the basis of bio-polymers, the use thereof, and method for the production thereof
CN101721751B (en) * 2008-10-10 2013-01-02 张阳德 Human tissue engineering support loaded with controlled-release cell growth factor and provided with hollow silicon dioxide ball with kernel and preparation method and applications thereof
US20100291182A1 (en) * 2009-01-21 2010-11-18 Arsenal Medical, Inc. Drug-Loaded Fibers
KR101065255B1 (en) * 2009-02-13 2011-09-16 김근형 New drug delivery system using electrospinning of biodegradable polymers
CN101559242B (en) * 2009-05-22 2015-07-29 广州迈普再生医学科技有限公司 A kind of can simultaneously as the nano artificial cerebral dura mater and preparation method thereof of drug controlled release system
WO2011029777A1 (en) 2009-09-11 2011-03-17 Basf Se Methods for producing coated polymer fibers
US9295859B2 (en) 2009-12-08 2016-03-29 The Procter & Gamble Company Porous, dissolvable solid substrate and surface resident coating comprising matrix microspheres
WO2011103152A1 (en) 2010-02-16 2011-08-25 The Procter & Gamble Company A porous, dissolvable solid substrate and surface resident coating comprising a zync pyrithione
CN101816627B (en) * 2010-04-16 2012-03-07 浙江大学 Synergistic treatment type multi-material sustained-release eye drop and preparation method
WO2012003365A1 (en) 2010-07-02 2012-01-05 The Procter & Gamble Company Filaments comprising an ingestible active agent nonwoven webs and methods for making same
MX2012015174A (en) 2010-07-02 2013-05-09 Procter & Gamble Filaments comprising an active agent nonwoven webs and methods for making same.
MX2012015187A (en) 2010-07-02 2013-05-09 Procter & Gamble Method for delivering an active agent.
US20180163325A1 (en) 2016-12-09 2018-06-14 Robert Wayne Glenn, Jr. Dissolvable fibrous web structure article comprising active agents
WO2012003300A2 (en) * 2010-07-02 2012-01-05 The Procter & Gamble Company Filaments comprising a non-perfume active agent nonwoven webs and methods for making same
CA2803371C (en) 2010-07-02 2016-04-19 The Procter & Gamble Company Process for making films from nonwoven webs
MX2013000201A (en) * 2010-07-02 2013-08-21 Procter & Gamble Methods of delivering a health care active by administering personal health care articles comprising a filament.
CA2803636C (en) 2010-07-02 2017-05-16 The Procter & Gamble Company Detergent product and method for making same
MX360481B (en) 2010-07-02 2018-11-05 Procter & Gamble Dissolvable fibrous web structure article comprising active agents.
CN101915797B (en) * 2010-07-27 2011-09-28 北京师范大学 Method for preparing electrostatic spinning immobilized laccase electrode
WO2012070028A1 (en) 2010-11-26 2012-05-31 University Of The Witwatersrand, Johannesburg A pharmaceutical dosage form
WO2012084441A1 (en) 2010-12-22 2012-06-28 Unilever Nv Compositions in the form of fibres
WO2012084427A1 (en) 2010-12-22 2012-06-28 Unilever Nv Compositions comprising structured non-aqueous liquid phase
CZ303244B6 (en) 2011-01-17 2012-06-13 Elmarco S.R.O. Carrier for oromucosal, especially sublingual application of physiologically active compounds
CN102251317B (en) * 2011-05-18 2013-01-16 东华大学 Preparation method of electrospun fibers with controllable drug release
WO2013124869A2 (en) * 2012-02-21 2013-08-29 Amrita Vishwa Vidyapeetham University The art, method,manner process and system of fibrous bio-degradable polymeric wafers for the local delivery of therapeutic agents in combinations
CN102631715A (en) * 2012-05-04 2012-08-15 江南大学 Preparation method of anti-coagulation nano fiber membrane
CN102670483B (en) * 2012-05-09 2014-04-02 上海交通大学 Electrostatic spinning fiber membrane preparation for treating hyperlipidemia and preparation method thereof
CN102697727B (en) * 2012-06-12 2014-01-08 东华大学 Method for preparing self-assembly ketoprofen liposome by electrostatic spinning technology
KR101454360B1 (en) 2012-08-31 2014-10-24 서울대학교산학협력단 A gelatin nanofibrous web containing Phaeodactylum triconutum extracts and wound dressing using the same
MX370280B (en) 2012-10-12 2019-12-09 Procter & Gamble Personal care composition in the form of a dissolvable article.
CZ308409B6 (en) * 2013-02-26 2020-08-05 Elmarco S.R.O. Preparation for the administration of at least one biologically and / or pharmaceutically active substance
CN105246469A (en) 2013-03-12 2016-01-13 活性纤维有限公司 Nanofibre and bioactive compositions and related methods
EP2813212A1 (en) 2013-06-10 2014-12-17 Zentiva, a.s. Drug formulation using API in nanofibers
US10202636B2 (en) * 2013-12-24 2019-02-12 General Electric Company Electrospun fibers for protein stabilization and storage
MX2016013616A (en) 2014-04-22 2017-02-28 Procter & Gamble Compositions in the form of dissolvable solid structures.
US9827173B2 (en) 2014-05-05 2017-11-28 The Procter & Gamble Company Porous dissolvable solid structure with two benefit agents and methods of forming an aqueous treatment liquor therefrom
US9867762B2 (en) 2014-05-05 2018-01-16 The Procter & Gamble Company Consumer product comprising a porous dissolvable solid structure and silicone conditioning agent coating
US9937111B2 (en) 2014-05-05 2018-04-10 The Procter & Gamble Company Consumer product comprising a fibrous web solid structure with a silicone conditioning agent coating
US9861559B2 (en) 2014-05-05 2018-01-09 The Procter & Gamble Company Consumer product comprising a porous, dissolvable, fibrous web solid structure with a silicone coating
US9877899B2 (en) 2014-05-05 2018-01-30 The Procter & Gamble Company Consumer product comprising a fibrous web structure with a silicone conditioning agent coating
US9861558B2 (en) 2014-05-05 2018-01-09 The Procter & Gamble Company Methods of forming an aqueous treatment liquor by dissolving a porous solid with a benefit agent coating
EP3622947A1 (en) * 2014-06-10 2020-03-18 Afyx Therapeutics A/S Compositions comprising electrohydrodynamically obtained fibres for administration of specific dosages of an active substance to skin or mucosa
CN105362269A (en) * 2014-09-01 2016-03-02 天津药物研究院 Saccharose containing roflumilast tablets and preparation method thereof
WO2016159240A1 (en) * 2015-03-31 2016-10-06 Ｏｒｔｈｏｒｅｂｉｒｔｈ株式会社 Method for manufacturing drug-containing biodegradable fiber material by electrospinning
CN108025477A (en) * 2015-07-07 2018-05-11 新加坡保健服务集团 Polymeric articles and its preparation
CN105327357B (en) * 2015-10-14 2019-01-11 北京科技大学 A kind of drug-loading system of hyaluronic acid and preparation method thereof of catechol modification
BR112018001978A2 (en) * 2015-11-19 2018-09-18 Dermtreat Aps pharmaceutical composition comprising electrohydrodynamically obtained fibers, composition with improved residence time over the application site
US20210069122A1 (en) * 2016-01-27 2021-03-11 Instar Technologies A.S. Oromucosal nanofiber carriers for therapeutic treatment
CN105727358B (en) * 2016-02-23 2019-01-22 广西易得佳医疗器械有限公司 Drug-loaded biological high-molecular composite nanometer tunica fibrosa and preparation method thereof
CN105663025A (en) * 2016-02-29 2016-06-15 浙江工业大学 Drug-containing microfilament and preparation method thereof
JP7162014B2 (en) 2017-01-23 2022-10-27 アフリックス セラピューティクス アー／エス Method for fabricating two-layer products based on electrospun fibers
ES2874787T3 (en) 2017-01-23 2021-11-05 Afyx Therapeutics As Method for the preparation of electrospun fibers with a high content of a bioadhesive substance
MX2019008762A (en) 2017-01-27 2019-09-18 Procter & Gamble Compositions in the form of dissolvable solid structures.
CN110167639B (en) 2017-01-27 2022-10-14 宝洁公司 Composition in the form of a soluble solid structure comprising effervescent agglomerated granules
JP6923673B2 (en) 2017-05-16 2021-08-25 ザ プロクター アンド ギャンブル カンパニーＴｈｅ Ｐｒｏｃｔｅｒ ＆ Ｇａｍｂｌｅ Ｃｏｍｐａｎｙ Conditioning hair care compositions in the form of soluble solid structures
CN107447366A (en) * 2017-08-03 2017-12-08 东华大学 A kind of sensitive medicament-carried sustained release nano fiber films of pH and its preparation method and application
KR102433420B1 (en) 2018-01-26 2022-08-18 더 프록터 앤드 갬블 캄파니 Water-Soluble Articles and Related Methods
JP7110356B2 (en) 2018-01-26 2022-08-01 ザ プロクター アンド ギャンブル カンパニー Water soluble unit dose article containing perfume
US11053466B2 (en) 2018-01-26 2021-07-06 The Procter & Gamble Company Water-soluble unit dose articles comprising perfume
KR20200086739A (en) 2018-01-26 2020-07-17 더 프록터 앤드 갬블 캄파니 Water soluble unit dose article containing enzyme
WO2019168829A1 (en) 2018-02-27 2019-09-06 The Procter & Gamble Company A consumer product comprising a flat package containing unit dose articles
JP7121944B2 (en) * 2018-05-07 2022-08-19 国立大学法人信州大学 Nanofiber and its manufacturing method
JP1639110S (en) 2018-07-16 2019-08-13
US10982176B2 (en) 2018-07-27 2021-04-20 The Procter & Gamble Company Process of laundering fabrics using a water-soluble unit dose article
US11666514B2 (en) 2018-09-21 2023-06-06 The Procter & Gamble Company Fibrous structures containing polymer matrix particles with perfume ingredients
WO2020159860A1 (en) 2019-01-28 2020-08-06 The Procter & Gamble Company Recycleable, renewable, or biodegradable package
EP3712237A1 (en) 2019-03-19 2020-09-23 The Procter & Gamble Company Fibrous water-soluble unit dose articles comprising water-soluble fibrous structures
JP7381613B2 (en) 2019-06-28 2023-11-15 ザ プロクター アンド ギャンブル カンパニー Dissolvable solid fibrous article containing anionic surfactant
EP3993757A1 (en) 2019-07-03 2022-05-11 The Procter & Gamble Company Fibrous structures containing cationic surfactants and soluble acids
USD939359S1 (en) 2019-10-01 2021-12-28 The Procter And Gamble Plaza Packaging for a single dose personal care product
JP2022551268A (en) 2019-10-14 2022-12-08 ザ プロクター アンド ギャンブル カンパニー Biodegradable and/or home compostable sachets containing solid items
WO2021097691A1 (en) 2019-11-20 2021-05-27 The Procter & Gamble Company Porous dissolvable solid structure
EP4065068A1 (en) 2019-12-01 2022-10-05 The Procter & Gamble Company Hair conditioner compositions with a preservation system containing sodium benzoate and glycols and/or glyceryl esters
USD962050S1 (en) 2020-03-20 2022-08-30 The Procter And Gamble Company Primary package for a solid, single dose beauty care composition
USD941051S1 (en) 2020-03-20 2022-01-18 The Procter And Gamble Company Shower hanger
USD965440S1 (en) 2020-06-29 2022-10-04 The Procter And Gamble Company Package
WO2022027067A1 (en) 2020-07-31 2022-02-03 The Procter & Gamble Company Water-soluble fibrous pouch containing prills for hair care
CN116472021A (en) 2020-08-11 2023-07-21 宝洁公司 Cleansing rinse-off hair conditioner compositions containing valine ester ethane sulfonate of canola oil alcohol
EP4196233A1 (en) 2020-08-11 2023-06-21 The Procter & Gamble Company Moisturizing hair conditioner compositions containing brassicyl valinate esylate
US11633336B2 (en) 2020-08-11 2023-04-25 The Procter & Gamble Company Low viscosity hair conditioner compositions containing brassicyl valinate esylate
EP4255384A1 (en) 2020-12-01 2023-10-11 The Procter & Gamble Company Aqueous hair conditioner compositions containing solubilized anti-dandruff actives
CN113041230B (en) * 2021-03-23 2022-06-24 浙江尖峰健康科技有限公司 Capsule shell of soft capsule and soft capsule prepared from capsule shell
WO2023145886A1 (en) * 2022-01-31 2023-08-03 三菱ケミカル株式会社 Nanofibers
CN114808184A (en) * 2022-03-11 2022-07-29 深圳市法鑫忠信新材料有限公司 Long-acting mosquito-repelling electrostatic spinning fiber and preparation method and application thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1527592A (en) * 1974-08-05 1978-10-04 Ici Ltd Wound dressing
US4855326A (en) * 1987-04-20 1989-08-08 Fuisz Pharmaceutical Ltd. Rapidly dissoluble medicinal dosage unit and method of manufacture
US5567439A (en) * 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US5869098A (en) * 1997-08-20 1999-02-09 Fuisz Technologies Ltd. Fast-dissolving comestible units formed under high-speed/high-pressure conditions
US5980941A (en) * 1997-08-20 1999-11-09 Fuisz Technologies Ltd. Self-binding shearform compositions
US6753454B1 (en) * 1999-10-08 2004-06-22 The University Of Akron Electrospun fibers and an apparatus therefor

Also Published As

Publication number Publication date
HUP0301130A3 (en) 2006-07-28
CA2396640A1 (en) 2001-08-02
AU772830B2 (en) 2004-05-06
AR028204A1 (en) 2003-04-30
KR20020082212A (en) 2002-10-30
MY129356A (en) 2007-03-30
EP1251829A4 (en) 2009-05-06
ZA200205989B (en) 2003-02-03
CN1396823A (en) 2003-02-12
TWI289061B (en) 2007-11-01
KR100806412B1 (en) 2008-02-21
PL356924A1 (en) 2004-07-12
NO20023338L (en) 2002-09-03
IL150642A0 (en) 2003-02-12
AU3113401A (en) 2001-08-07
MXPA02007298A (en) 2002-12-09
NZ519992A (en) 2004-04-30
JP2003521493A (en) 2003-07-15
CN1223340C (en) 2005-10-19
NO20023338D0 (en) 2002-07-11
WO2001054667A1 (en) 2001-08-02
EP1251829A1 (en) 2002-10-30
HUP0301130A2 (en) 2003-09-29

Similar Documents

Publication Publication Date Title
BR0107869A (en) Electrogenated pharmaceutical compositions
PL357944A1 (en) Intradermal-penetration agents for topical local anesthetic administration
CY1108532T1 (en) UNIONS AND COMPOSITIONS FOR PROVIDING ACTIVE AGENTS
MY119403A (en) Novel compounds with analgesic effect.
PT1093819E (en) COMPOUNDS AND COMPOSITIONS FOR THE SUPPLY OF ACTIVE AGENTS
IL135258A0 (en) Bioadhesive compositions and methods for topical administration of active agents
BR0108435A (en) Formulation and use of low dose entecavir
AR018109A1 (en) ADMINISTRABLE GALENIC FORMULATION BY ORAL ROUTE THAT ALLOWS AN IMPROVED ABSORPTION OF ACTIVE PRINCIPLES, USE OF AN ABSORPTION MAJORATING AGENT TO PREPARE AN ADMINISTRABLE DOSAGE METHOD BY ORAL ROUTE AND PROCEDURE TO PREPARE THE GINAL FORMULA
ES2182357T3 (en) NEW USE OF BUDESONIDE AND FORMOTEROL.
BG105568A (en) Pharmaceutical compositions for modified release of an insulin sensitiser and another antidiabetic agent
MY132705A (en) Novel compounds with analgesic effect
HK1024865A1 (en) Pharmaceutical compositions comprising a mixture of autocross-linked hyaluronic acid and nonautocross-linked hyaluronic acid and their use for the treatment of arthropathies
BG66093B1 (en) Controlled release compositions comprising nimesulide
ID27504A (en) NEW ORAL FORMULATION
BR0309544A (en) Pharmaceutical preparation containing oxycodone and naloxone
IL140930A0 (en) Compounds and compositions for delivering active agents
ATE275393T1 (en) SOLID DISPERSIONS WITH NITRATACTIVE ACTIVE INGREDIENTS
EP1139753A4 (en) Formulations for treating disease and methods of using same
AU9018898A (en) Phosphazole-containing nucleoside analogs, related compounds, pharmaceutical compositions thereof, and their use in in vitro medicinal treatments
SE9802208D0 (en) Novel compounds
IT1263840B (en) ORAL FORMULATIONS OF UBIDECARENONE IN THE FORM OF CAPSULES
BR0112847A (en) Use of a solid dosage form
ATE491447T1 (en) COMPOSITIONS CONTAINING FLAVONOIDS AND TOCOTRIENOLS AND USES THEREOF
BR0113165A (en) 4-Pyrimidinamine derivatives, pharmaceutical compositions and related methods
AR036321A1 (en) METHOD AND PHARMACEUTICAL FORMULATION FOR THE TREATMENT OF LATE APPEARANCE DYSCINESIA.

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements